site stats

Cassiopeia study myeloma

Web22 Oct 2024 · Data from a subgroup analysis of CASSIOPEIA that were presented at the 17th International Myeloma Workshop also showcased an improvement in minimal residual disease (MRD) negativity rates and... Web28 Mar 2024 · The CASSIOPEIA phase 3 study included 1085 NDMM ... with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a ...

A Study to Evaluate Daratumumab in Transplant Eligible …

Web13 Sep 2024 · CASSIOPEIA is a two-part, open-label, randomised, phase 3 trial of patients aged 18–65 years with newly diagnosed multiple myeloma and Eastern Cooperative … Web10 Dec 2024 · For example, the CASSIOPEIA study evaluated daratumumab, bortezomib, thalidomide, and dexamethasone (dara-VTd) vs VTd in newly diagnosed patients … get a ccw permit online https://agatesignedsport.com

Current Advances in Multiple Myeloma: A Post International Myeloma ...

Web28 Dec 2024 · Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2024;394(10192):29-38. Web23 Mar 2024 · Multiple myeloma is a hematologic cancer in which clonal plasma-cell proliferation leads to complications and death. 1 Initial treatment for newly diagnosed multiple myeloma depends on whether a ... Web26 Oct 2024 · The open-label, multicenter, two-part CASSIOPEIA study (NCT02541383) was designed to evaluate the safety and effectiveness of adding Darzalex to standard pre-transplant therapy in a group of untreated multiple myeloma patients who were eligible for … christmas homily for kids

Overall survival with daratumumab, bortezomib, melphalan, and ...

Category:Overall survival with daratumumab, bortezomib, melphalan, and ...

Tags:Cassiopeia study myeloma

Cassiopeia study myeloma

FDA approves daratumumab for transplant-eligible multiple myeloma

Web12 Nov 2024 · The phase III CASSIOPEIA trial, which first began enrolling in 2015, was designed to assess the efficacy of daratumumab in transplant-eligible patients with … Web29 Aug 2024 · The study, CASSIOPEIA, is the first study to demonstrate the clinical benefit of daratumumab plus the standard-of-care VTd in transplant-eligible newly diagnosed patients with multiple myeloma. 5 Based on the CASSIOPEIA study, the U.S. Food and Drug Administration (FDA) granted a Priority Review designation to a supplemental …

Cassiopeia study myeloma

Did you know?

WebMethods: CASSIOPEIA is an ongoing randomised, open-label, active-controlled, parallel-group, phase 3 trial done at 111 academic and community practice centres in Europe. … WebThe subgroup analysis for the type of myeloma evaluated IgG versus non-IgG disease and included patients with measurable disease in serum. A high-risk cytogenetic profile was …

Web13 Sep 2024 · CASSIOPEIA, a two-part, phase 3 trial, has brought daratumumab to the forefront of efforts aimed at improving outcome for transplant-eligible patients. Part 1 … WebASCO 2024 CASSIOPEIA part 1 trial results During the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, US, the Multiple Myeloma Hub Co-Chair, Philippe Moreau, presented part 1 results of CASSIOPEIA trial You need to enable JavaScript to run this app.

Web3 Nov 2024 · With one cycle of any myeloma-directed therapy being allowed before enrollment, the GMMG-CONCEPT trial enabled even ultra HR patients including plasma cell leukemia and patients primary... Web24 Aug 2024 · Study design. This was an open-label, nonrandomized, multicenter, multiarm, phase 1b study in a large number of patients (N = 103). Treatment arms evaluated …

Web3 Jun 2024 · Multiple myeloma (MM) treatment has considerably improved in the past 15–20 years. The current paradigm for transplant-eligible newly diagnosed MM (NDMM) patients consists of induction, stem-cell...

WebThis study, conducted on behalf of the Intergroupe Francophone du Myelome (IFM) and Hemato-Oncologie voor Volwassenen Nederland (HOVON), was a phase III, randomized … get a cdl texasWeb6 Jul 2024 · CASSIOPEIA is the first study showing the clinical benefit of daratumumab plus standard of care in transplant-eligible patients with newly diagnosed multiple myeloma. Funding: The Intergroupe Francophone du Myélome and Dutch-Belgian … get a cdl class aWeb14 Nov 2024 · While CASSIOPEIA had several hundred patients, 7 GRIFFIN only had a little over [100] patients in each arm. 9 At 24 months, the PFS remains very high in both arms, and the same [is true] for OS, [although the data are] not mature yet. Of course, with the addition of agents, toxicity increases. getac docking station troubleshooting